Apatinib for non-first-line treatment as an anti-angiogenesis agent in metastatic cancer:an open-label,single-arm phase II trial

Trial Profile

Apatinib for non-first-line treatment as an anti-angiogenesis agent in metastatic cancer:an open-label,single-arm phase II trial

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2017

At a glance

  • Drugs Apatinib (Primary)
  • Indications Solid tumours
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top